cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Syros Pharmaceuticals Inc
21 own
41 watching
Current Price
$0.24
$0.03
(13.21%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
244M
52-Week High
52-Week High
7.96000
52-Week Low
52-Week Low
0.18300000
Average Volume
Average Volume
2.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization244M
icon52-Week High7.96000
icon52-Week Low0.18300000
iconAverage Volume2.8M
iconDividend Yield--
iconP/E Ratio--
What does the Syros Pharmaceuticals Inc do?
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Read More
How much money does Syros Pharmaceuticals Inc make?
News & Events about Syros Pharmaceuticals Inc.
Zolmax
1 year ago
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS Get Rating) has earned a consensus rating of Moderate Buy from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. ...
Business Wire
1 year ago
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth...
Business Wire
1 year ago
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene...
Ticker Report
2years ago
Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS Get Rating) have earned a consensus rating of Moderate Buy from the six analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have ...
Business Wire
2years ago
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023. We are entering 2023 with a singular focus on...
Frequently Asked Questions
Frequently Asked Questions
What is Syros Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Syros Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Syros Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Syros Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Syros Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Syros Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Syros Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Syros Pharmaceuticals Inc?
plus_minus_icon
What percentage is Syros Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Syros Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.24
$0.03
(13.21%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$0.40
$-0.00 (-0.97 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$65.84
$1.82 (2.84 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$1.50
$-0.23 (-13.08 %)
GENERATION BIO CO
GENERATION BIO CO
$0.87
$-0.05 (-5.39 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$0.40
$-0.00 (-0.97 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$65.84
$1.82 (2.84 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$1.50
$-0.23 (-13.08 %)
GENERATION BIO CO
GENERATION BIO CO
$0.87
$-0.05 (-5.39 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00